Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma

Liver

Volumn 22, Issue 3, 2002, Pages 259-268

  Li, Kay K W ^a   Ng, Irene O L ^b   Fan, S T ^b   Albrecht, Jeffrey H ^c   Yamashita, Katsumi ^d   Poon, Randy Y C ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cell cycle; Cyclin; Cyclin dependent kinase; Hepatocellular carcinoma; Liver

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; LIVER EXTRACT; PROTEIN P21; CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN TISSUE; LIVER; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ENZYMOLOGY; HELA CELL; IMMUNOBLOTTING; LIVER TUMOR; METABOLISM; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS;

CARCINOMA, HEPATOCELLULAR; CYCLIN-DEPENDENT KINASES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ACTIVATION; HELA CELLS; HUMAN; IMMUNOBLOTTING; LIVER; LIVER NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN P34CDC2; PROTEIN-SERINE-THREONINE KINASES; SUPPORT, NON-U.S. GOV'T; CDC2 PROTEIN KINASE; CDC2-CDC28 KINASES; CYCLIN-DEPENDENT KINASE 2; HUMANS;

EID: 0035990954     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0106-9543.2002.01629.x     Document Type: Article

References (52)

1. Cyclin-dependent kinases: Engines, clocks, and microprocessors
2. Cell cycle control
3. Cell cycle regulators and human hepatocarcinogenesis
4. Overexpression of cyclin A, but not Skp 2 correlates with the tumour relapse of human hepatocellular carcinoma
5. Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma
6. Enchanced expression of cyclin E and cyclin A in human hepatocellular carcinomas
7. Hepatitis B. virus integration in a cyclin A gene in a hepatocellular carcinoma
8. Modification of cyclin A expression by hepatitis B virus, DNA integration in a hepatocellular carcinoma
9. Association of downregulation of cyclin D 1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepato-cellular carcinoma
10. Expression and prognostic roles of the G 1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence
11. Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma
12. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma
13. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma
14. Telomerase activity correlates with cell cycle regulators in human hepatocellular carcinoma
15. Germ-line mutations of the p16INK4 (MTS1) gene occur in a subset of patients with hepatocellular carcinoma
16. P16 (INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma
17. High frequency of p16INK4A gene alterations in hepatocellular carcinoma
18. Inactivation of p16INK4 in hepatocellular carcinoma
19. Loss oF P16 (INK4) protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression
20. Alterations of CDKN2 (MTS1/p16INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers
21. Homozygous deletions of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma
22. Infrequent alterations of the p16INK4A gene in liver cancer
23. Mutational study of p16CDKN2/MTS1/INK4A and p57KIP2 genes in hepatocellular carcinoma
24. Analysis of CDKN2A. CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma
25. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan
26. CDKN2 mutation is infrequent in german hepatocellular carcinoma
27. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population
28. Reduced p21 (WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas
29. Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma
30. P21/WAF1 P53 and PCNA. expression and p53 mutation status in hepatocellular carcinoma
31. Who binds wins: Competition for PCNA rings out cell-cycle changes
32. Cloning and sequence of the human nuclear protein cyclin: Homology with DNA-binding proteins
33. Analysis of proliferating hepatocytes using a monoclonal antibody against proliferating cell nuclear antigen/cyclin in embedded tissues from various liver diseases fixed in formaldehyde
34. Immunohistochemical detection of proliferating cell nuclear antigen in hepatocellular carcinoma: Relationship to histological grade
35. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis
36. Proliferating cell nuclear antigen in hepatocellular carcinoma and small cell liver dysplasia
37. Analyses of proliferating cell nuclear antigen-positive cells in hepatocellular carcinoma: Comparisons with clinical findings
38. Proliferating cell nuclear antigen and grade of malignancy in small hepatocellular carcinoma - Evaluation in US-guided specimens
39. Evaluation of hepatic proliferative activity in chronic liver diseases and hepatocellular carcinomas by proliferating cell nuclear antigen (PCNA) immunohistochemical staining of methanol-fixed tissues
40. Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma
41. Hepatocellular carcinoma: Surgical treatment and prognostic variables in 56 patients
42. Expression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: Relevance to tumour characteristics and prognosis
43. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival
44. Clinicopathologic features and prognosis of resected hepatocellular carcinomas of varied sizes with special reference to proliferating cell nuclear antigen
45. Proliferative activity of hepatocytes in chronic viral hepatitis as revealed by immunohistochemistry for proliferating cell nuclear antigen
46. Redistribution of the CDK inhibitor p27 between different cyclin. CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation
47. Involvement of p2l and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver
48. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells
49. Hepatocellular carcinoma cell cycle: Study of Long-Evans cinnamon rats
50. Cloning sequencing, and chromosomal localization of two tandemly arranged human pseudogenes for the proliferating cell nuclear antigen (PCNA)
51. Identification of carrot cDNA clones encoding a second putative proliferating cell-nuclear antigen, DNA polymerase delta auxiliary protein
52. Analysis of the epitopes of proliferating cell nuclear antigen recognized by monoclonal antibodies